BRAF and melanoma: First, the long-term survival and cost-effectiveness model essentially relied on the validity and generalizability of the IMspire150 trial, which was the first phase 3 randomized clinical trial to investigate a triplet immuno-targeted therapy regimen in patients with previously untreated metastatic or unresectable locally advanced melanoma with a BRAF V600 variation.